Clinical Summary: Obstetric Risk Associated With Stimulant Versus Nonstimulant Treatment During Pregnancy
Pregnant patients with attention-deficit/hyperactivity disorder and their clinicians often have to choose between continuing medication and accepting uncertain obstetric risk, while discontinuation can also impair functioning. This study addresses that everyday clinical dilemma by comparing stimulant and nonstimulant exposure during pregnancy across a broad range of maternal and placental outcomes in a very large real-world cohort.
Key Findings
- Compared with no medication, stimulant exposure was associated with significantly higher risk for most adverse outcomes, with increased-risk ORs ranging from 1.21 for LGA to 1.85 for gestational hypertension and placenta previa; there was no significant effect for gestational diabetes.
- Compared with no medication, nonstimulant exposure was associated with significantly higher risk for most obstetric outcomes, with ORs ranging from 1.12 for gestational diabetes and placenta previa to 5.70 for placental abruption.
- In stimulant versus nonstimulant comparisons, stimulant exposure was associated with higher odds of placenta previa and LGA, and significantly lower odds of gestational diabetes, placental abruption, IUGR, and preterm delivery; significant ORs ranged from 0.40 for lower odds of placental abruption to 2.30 for higher odds of placenta previa.
- Within the stimulant group, 3,039 (87.7%) had more than 1 stimulant medication entry recorded during pregnancy, which may reflect coding of different formulations or switching between products rather than simultaneous exposure to multiple distinct stimulants.
- Only 14.8% of the nonstimulant group had a documented ADHD diagnosis in their chart, compared with nearly half of the stimulant group, indicating substantial clinical heterogeneity across medication-exposed groups.
Both stimulant and nonstimulant treatment during pregnancy were associated with elevated obstetric risk after adjustment for measured baseline differences, and nonstimulants were not a clearly safer alternative. For pregnant patients with attention-deficit/hyperactivity disorder, medication decisions should be individualized with shared decision-making and active monitoring across gestation.
Practice Implications
- Do not assume nonstimulant ADHD medication is lower risk in pregnancy; compared with no medication, nonstimulant exposure was associated with increased risk across gestational diabetes, hypertensive disorders, placental complications, IUGR, preterm delivery, and spontaneous abortion.
- If stimulant treatment is continued during pregnancy, monitor closely for hypertensive and placental complications, because stimulant exposure showed increased-risk ORs up to 1.85 for gestational hypertension and placenta previa versus no medication.
- Use head-to-head differences to guide counseling when weighing stimulant versus nonstimulant treatment: stimulant exposure had higher odds of placenta previa and LGA, but lower odds of gestational diabetes, placental abruption, IUGR, and preterm delivery than nonstimulant exposure.
- Interpret these data as observational signal-detection evidence rather than causal safety estimates, especially because medication exposure was defined by 2 or more EHR medication records during pregnancy and the nonstimulant group was small (575).
